Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Metabolic bone disease is a major public health concern, especially when it manifests as hip fracture which carries significant morbidity and mortality. Individuals with neurological disease are at higher risk of osteopenia, osteoporosis and fragility fracture compared to age-matched controls, yet this is under-appreciated by these patients. Clinician attention to this topic is therefore of importance and should address the bone health of men as well as women, a group in whom it may be an under-recognised problem. Evidence for optimal management of bone health in neurological disease remains to be defined, but a growing literature provides some useful guidance. This review focuses on two conditions, multiple sclerosis and Parkinson's disease, where research has been active over recent years. In neuroinflammation, shared immunological pathways between bone and brain are a current domain of interest and it will be intriguing to interrogate the action of emerging immunotherapies on these dual compartments.

More information Original publication

DOI

10.1007/s11914-016-0320-5

Type

Journal article

Publication Date

2016-10-01T00:00:00+00:00

Volume

14

Pages

199 - 210

Total pages

11

Keywords

Bone mineral density, Fracture, Multiple sclerosis, Osteopenia, Osteoporosis, Parkinson’s disease, Accidental Falls, Bone Density Conservation Agents, Bone Diseases, Metabolic, Calcium, Dietary, Exercise Therapy, Humans, Immunotherapy, Multiple Sclerosis, Osteoporosis, Osteoporotic Fractures, Parkinson Disease, Risk Factors, Vitamin D